Secondary analysis of a 12-week trial of N-acetylcysteine vs placebo in 302 adults with cannabis use disorder found four craving trajectories: low (41%), moderate-decreasing (38%), moderate-stable (11%) and high (10%); the high class had 96% cannabis-positive urine tests.
Secondary analysisn = 302
Alias-Ferri et al. Longitudinal craving profiles in cannabis use disorder: A latent class growth analysis of the achieving cannabis cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) (CTN-0053) trial